# US 2009/0270482 A1 · Analysis of methylated nucleic acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270482 A1
- Document ID: US20090270482A1
- Status: Published application
- Kind: A1
- Application number: 11/571,026
- Filed: 2005-03-03
- Published: 2009-10-29
- Earliest claimed: 2004-06-18
- Inventors: Dirk Schuebeler; Michael Philippe Weber
- Web page: https://patentgrep.com/patent/US20090270482A1

## CPC

- C12N 15/1003: {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- A61P 35/00: Antineoplastic agents
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method for analysis methylation patterns in DNA and identifying aberrantly methylated genes in disease tissue. The invention also provides a method of identifying novel targets for therapeutic intervention and disease markers. Novel cancer targets are provided.

## Claims

### Claim 1

A method for enriching methylated nucleic acid fragments in a sample of nucleic acid fragments comprising the steps of:
(a) contacting the sample of nucleic acid fragments with an antibody specific to a methylated nucleoside under conditions suitable for binding of the antibody to the methylated nucleoside;
(b) selecting nucleic acid fragments bound to the antibody specific to a methylated nucleoside.

### Claim 2 (depends on 1)

The method of claim 1, further comprising before step (a):
separating the strands of double-stranded nucleic acid fragments in the sample.

### Claim 3 (depends on 1)

The method of claim 1 further comprising the further step of (c) characterising one or more of the methylated nucleic acid fragments.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 9)

The method of claim 9 wherein the solid substrate binds specifically to the antibody specific to a methylated nucleoside.

### Claim 11 (depends on 10)

The method of claim 10 wherein the solid substrate comprises a second antibody specific for the antibody specific to a methylated nucleoside.

### Claim 12 (depends on 9)

The method of claim 9 wherein the solid substrate is in the form of beads.

### Claim 13 (depends on 9)

The method of claim 9 wherein the solid substrate is magnetic.

### Claim 14

(canceled)

### Claim 15 (depends on 14)

The method of claim 14 wherein detaching the methylated nucleic acid fragments from the antibody specific to a methylated nucleoside comprises incubating the nucleic acid fragments bound to the first antibody with a proteinase.

### Claim 16 (depends on 3)

A method of characterising the methylation status of a genomic DNA sample comprising:
(i) fragmenting the genomic DNA sample to give a sample of nucleic acid fragments, and
(ii) carrying out the method of any one of claim 3 on the sample of nucleic acid fragments obtained in (i).

### Claim 17 (depends on 3)

A method of comparing the methylation status of at least two samples of nucleic acid fragments comprising:
(i) carrying out the method of any one of claim 3 on each sample of nucleic acid fragments, and
(ii) comparing the results obtained in (i) from one nucleic acid sample with that of at least one other nucleic acid sample.

### Claim 18 (depends on 3)

A method of diagnosis or prognosis of a disease associated with methylation of a specific nucleic acid fragment in an individual comprising:
(i) carrying out the method of any one of claim 3 on a sample of nucleic acid fragments from the individual;
(ii) correlating the result obtained in (i) with the disease state of the individual.

### Claim 19 (depends on 3)

A method for detection of changes in nucleic acid methylation in a patient over time comprising:
(i) obtaining a tissue specimen from the patient at a time point;
(ii) repeating step (i) for at least one further time point;
(iii) extracting nucleic acid from each tissue specimen to provide a sample of nucleic acid for each time point, and
(iv) carrying out the method of any one of claim 3 on each nucleic acid sample for each time point to characterise whether, and/or to what extent, the nucleic acid sequence is methylated.

### Claim 20 (depends on 19)

A method for correlating changes in nucleic acid methylation with the clinical symptoms of a disease comprising the steps of claim 19 and further comprising:
(a) recording the clinical symptoms of a disease observed in the patient at each time point, and
(b) comparing the clinical symptoms recorded at each time point with the results obtained in step (iv).

### Claim 21 (depends on 19)

The method of claim 19 further comprising storage of each tissue specimen and carrying out step (ii) for a plurality of specimens at the same time.

### Claim 22 (depends on 18)

The method of claim 18 wherein the disease is cancer.

### Claim 23

A method of treatment of cancer comprising modulating the activity or expression of one of more of KIAA0789, FOXF1, ADAM12, MGC48625, SHH, PAX6, FLJ25439, TAZ, GATA3, TGFb2, ZNF566, ALX4, LOC283514 and DAP.

### Claim 24

Use of one any one of KIAA0789, FOXF1, ADAM12, MGC48625, SHH, PAX6, FLJ25439, TAZ, GATA3, TGFb2, ZNF566, ALX4, LOC283514 and DAP in an assay to identify modulators thereof for the treatment of cancer.

### Claim 25

A method for determining whether a human tissue is predisposed to a neo-plastic transformations comprising determining whether in a cell from the tissue a nucleic acid molecule selected from the group consisting of KIAA0789, FOXF1, ADAM12, MGC48625, SHH, PAX6, FLJ25439, TAZ, GATA3, TGFb2, ZNF566, ALX4, LOC283514 and DAP is absent, present in a mutant form or down-regulated through epigenetic mechanisms.

### Claim 26

A method of treating or inhibiting cancer in a patient in need of such treatment comprising the steps of administering to said patient a vector capable of expressing a gene selected from the group consisting of KIAA0789—accession no. XM—033133—, FOXF1, ADAM12, MGC48625, SHH, PAX6, FLJ25439—accession no. NM—144725—, TAZ, GATA3, TGFb2, ZNF566—accession no. NM—032838—, ALX4—accession no. NM—021926—, LOC283514 and DAP.

### Claim 27

A pharmaceutical composition comprising any one or more of the genes selected from the group consisting of KIAA0789, FOXF1, ADAM12, MGC48625, SHH, PAX6, FLJ25439, TAZ, GATA3, TGFb2, ZNF566, ALX4, LOC283514 and DAP active fragments thereof, their expression products and antibodies to their expression products, and an inert carrier.
